Malaria in Middle East, North Africa, Afghanistan & Pakistan
Country-level malaria mortality data for Middle East, North Africa, Afghanistan & Pakistan. Age-standardized death rates per 100,000 population from the IHME Global Burden of Disease Study.
| # | Country | Rate |
|---|
This page presents malaria mortality data for countries in Middle East, North Africa, Afghanistan & Pakistan, using age-standardized death rates per 100,000 population from the Institute for Health Metrics and Evaluation (IHME). Regional analysis reveals significant variation in disease burden between countries, reflecting differences in healthcare infrastructure, socioeconomic conditions, environmental risk factors, and public health policy implementation across Middle East, North Africa, Afghanistan & Pakistan.
Malaria is a parasitic disease caused primarily by Plasmodium falciparum and Plasmodium vivax, transmitted through the bite of infected female Anopheles mosquitoes. The parasite invades red blood cells, triggering cyclical fevers, haemolytic anaemia, and — in severe cases — cerebral malaria, respiratory distress, and multi-organ failure. Children under five and pregnant women in endemic regions bear the heaviest mortality burden. Sub-Saharan Africa accounts for approximately 95% of the world's 620,000 annual malaria deaths, with Nigeria and the Democratic Republic of the Congo together responsible for nearly 40% of the global toll. The disease has shaped human evolution itself, driving selection for sickle-cell trait and other haemoglobin variants that confer partial resistance. Between 2000 and 2015, scaled-up interventions — insecticide-treated bed nets, indoor residual spraying, rapid diagnostic tests, and artemisinin-based combination therapies — reduced malaria mortality by roughly 60%. However, progress has stalled since 2015, with rising insecticide resistance and climate-driven range expansion posing new threats. The Middle East and North Africa region encompasses wealthy Gulf states with well-resourced health systems and conflict-affected nations where healthcare infrastructure has been severely damaged, creating extreme within-region disparities. In the Middle East & North Africa, malaria mortality aligns roughly with global averages, though this regional figure masks stark contrasts between conflict-affected states and stable high-income economies.
Malaria prevention relies on vector control, chemoprevention, and vaccination. Long-lasting insecticidal nets (LLINs) remain the most cost-effective intervention, averting an estimated 68% of malaria cases prevented since 2000. Seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine plus amodiaquine protects children in the Sahel during peak transmission months. The RTS,S/AS01 vaccine (Mosquirix), recommended by the WHO in 2021, and the more effective R21/Matrix-M vaccine approved in 2023, represent breakthroughs in long-sought immunisation against the parasite.
The mortality estimates presented on this page are derived from the Global Burden of Disease (GBD) study, produced by the Institute for Health Metrics and Evaluation (IHME). The GBD synthesizes data from vital registration systems, verbal autopsies, cancer registries, and surveillance networks across more than 200 countries and territories. Death rates are expressed per 100,000 population and are age-standardized, which adjusts for differences in age structure between populations so that comparisons across countries and over time reflect genuine differences in mortality risk rather than demographic composition.
The dataset typically covers the period from 1990 to 2023, although availability varies by country and cause. When interpreting the figures for malaria in Middle East, North Africa, Afghanistan & Pakistan, note that higher age-standardized rates indicate a greater mortality burden independent of whether a country's population is older or younger. Trends over time reveal whether public health interventions, economic development, and health system improvements have reduced or increased the toll of this condition in the region.
Disease-specific death rates measure the number of deaths directly attributed to malaria per 100,000 people, after accounting for age structure. These rates capture both the prevalence of the condition and the likelihood of a fatal outcome once affected. In Middle East, North Africa, Afghanistan & Pakistan, variation across countries may reflect differences in disease prevalence, access to treatment, diagnostic capacity, and the presence of comorbidities. Examining trends alongside health expenditure and intervention coverage helps identify where policy action has been most effective.